Discussions on Fair Pricing of Medicines at the Swedish Health Economics Days
The Swedish Health Economics Association (SHEA) held its annual conference, offering valuable insights into key topics in health economics.
Market Access
-
-
Sweden’s TLV Updates Reimbursement Model for Rare Diseases
Sweden has introduced a new reimbursement model for orphan drugs, likely to increase treatment options for rare diseases. At the same time, pharmaceutical companies are now expected to provide local evidence.
-
An Experienced Researcher seeks answers for their clients
Johan Rehnberg started working as a Scientific Advisor at Medaffcon’s Swedish office in August 2024. He is a dynamic researcher who values opportunities to learn new things and develop his skills – opportunities that Medaffcon provides.
-
Medaffcon’s Market Access Team Prepares Nordic Projects under the Leadership of Simo Jääskeläinen
Medaffcon’s Market Access team welcomed a new leader in mid-November, as Simo Jääskeläinen returned to his familiar workplace after a six-year hiatus.
-
Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
-
Medaffcon’s Patient Dynamics Tool Helps Focus and Find the Right Actions
Are you employed in the pharmaceutical industry and seeking insights into your product's position within the Finnish market? Then Patient Dynamics is the ideal tool for you. Developed by Medaffcon, Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
-
Renewable drug therapy challenges the current complex drug evaluation system
“Renewable drug therapy challenges the current complex drug evaluation system,” states Lauri Pelkonen, a leading expert at the Ministry of Social Affairs and Health (STM). For this reason, the evaluation activity is being reformed to better respond to changes in the operating environment.
-
The EU introduces changes to the assessment of medicines: EU HTA application in evaluations will gradually start next year
The EU introduces changes to the assessment of medicines: EU HTA application in evaluations will gradually start next year
-
The leading European HEOR meeting – ISPOR Europe – is approaching
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
-
Medaffcon answers call for its solutions-oriented data approach in Sweden
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
-
Timo Karvinen appointed to Medaffcon’s Market Access team
Timo Karvinen joined Medaffcon’s Market Access team as an expert in the beginning of May. In addition to his extensive expertise, he also brings a whole new service concept to Medaffcon.
-
Medaffcon’s Market Access team provides a vantage point to the entire industry
The Market Access team works actively with different actors, while helping customers in processes related to market access and market presence and in strategic planning.
-
Heini Honkanen appointed as Medaffcon’s Market Access Lead
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
-
Greetings from ISPOR: the use of Real World Evidence is becoming more common
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
-
RWE complements the overall picture of the authorities
In health economic studies, real world evidence (RWE) can produce additional knowledge, especially on the...
-
Real world evidence supports the market access of medicines – teduglutide as an example
We already have clinical medicine trials. Why on earth do we also need real world...
-
Real-world evidence completes clinical trials – the significance of data may increase in the future
RWE or real-world evidence provides authorities assessing pharmacotherapies with data on the prevalence of a...
-
Medical authority values the consistency of health economic evaluations
Health economic evaluations bring additional information to the authorities’ decision-making concerning medicinal products. How does...
-
Uncertainty is always present when assessing the introduction of a new medicine
From the perspective of decision-making, it is important that a health economic evaluation conducted on...
-
National price negotiation of hospital-only medicinal products is not an auction
HUS Pharmacy Director Kerstin Carlsson reveals the process of national price negotiation of hospital-only medicinal...
-
LINK Medical and Medaffcon join forces in Real World Evidence (RWE) and Market Access to offer customers full support across the Nordics
OSLO, Norway/ ESPOO, Finland May 24, 2021 LINK Medical, the Northern European clinical research organization...
-
Pharmaceutical Pricing and Market Access of Medicine Products in Finland
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes...
-
Finnish pricing and reimbursement landscape
Pricing and reimbursement in Finland Pharmaceuticals Pricing Board (PPB), operating under the Ministry of Social...
-
Managed entry agreements facilitate the access of new medicines
Public health authorities and pharmaceutical companies have searched for alternative funding formulas to share the...
-
Real world evidence (RWE) supported health technology assessment (HTA)
Demonstrating that a health technology, e.g. a product, procedure or any intervention, is worth its...
-
Risk-Sharing Agreements in Finland
Risk-sharing agreements (RSA) are one of the most interesting and debated topics in the Finnish...
-
Conditional reimbursement facilitates the introduction of new treatments
Learn about conditional reimbursement from the interview with CEO Jarmo Hahl, Medaffcon Oy. There’s often...
-
Risk Sharing Models in Finnish Hospitals 2017-study report now available!
Like already mentioned in my previous post it is known that different Risk-Sharing Models have...
-
Risk Sharing Models in Finnish Hospitals 2017 -study
As we all know different Risk-Sharing Models (RSM) have been varyingly in use in different...
-
Indicators for Assessing Treatment Effectiveness
Pharma Industry Finland commissioned a report from Medaffcon concerning how effectiveness could be assessed in...
-
Risk Sharing Models – Three perspectives
In our customer event in April, we examined risk-sharing models from three different perspectives. Director...
-
Medaffcon and Pharma Industry Finland begin a study in order to produce indicators for measuring effectiveness in healthcare
The assessment of treatment effectiveness should hold a central role in healthcare, in order to...
-
Adaptive Pathways – faster access for end users to innovative medicines?
The precondition for a medicinal product to receive a marketing authorisation is that the product...
-
Assessment of hospital medicines
Summary of Miia Turpeinen’s speech: Miia Turpeinen, Senior Medical Officer at Oulu University Hospital catchment...